01. Ongoing Clinical Trials
Ongoing Mesothelioma Clinical Trials
Clinical trials are currently in progress to evaluate new mesothelioma treatment protocols. Ongoing clinical trials may accept new patients while testing on already enrolled patients. However, this timeframe is often short and then no new patients are admitted to the trials. Please note that the enrollment period for the following mesothelioma studies has concluded and no new participants are being recruited at this time.
The purpose of these studies is to determine both the safety and effectiveness of new mesothelioma drugs and treatment therapies. Click on a link to learn more about a study and to get updated information.
02. List of Ongoing Clinical Trials
List of Ongoing Mesothelioma Clinical Trials Not Recruiting Patients
Provided below is a list of mesothelioma clinical trials that are not recruiting or enrolling participants. Click on a link to learn more about each study.
First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin
Conditions: Mesothelioma
Last Updated: June 29, 2021
Status: Active, not recruiting
Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma
Conditions: Mesothelioma
Last Updated: June 15, 2021
Status: Active, not recruiting
Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53
Conditions: Neoplasms
Last Updated: June 14, 2021
Status: Active, not recruiting
Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma
Conditions: Mesothelioma, Lung Neoplasms
Last Updated: June 11, 2021
Status: Active, not recruiting
Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
Conditions: Mesothelioma, Lung Neoplasms
Last Updated: June 2, 2021
Status: Active, not recruiting
Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study
Conditions: Lymphoma, Sarcoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Mesothelioma, Sarcoma, Synovial, Carcinoma, Medullary
Last Updated: May 26, 2021
Status: Active, not recruiting
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Conditions: Neoplasms
Last Updated: May 21, 2021
Status: Active, not recruiting
Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma
Conditions: Mesothelioma
Last Updated: May 20, 2021
Status: Active, not recruiting
Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: May 19, 2021
Status: Active, not recruiting
Psychosocial Needs and Exploration of Online Support for Patients With Mesothelioma
Conditions: Mesothelioma
Last Updated: May 10, 2021
Status: Active, not recruiting
A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors
Conditions: Neoplasms
Last Updated: May 3, 2021
Status: Active, not recruiting
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
Conditions: Mesothelioma, Lung Neoplasms
Last Updated: April 30, 2021
Status: Active, not recruiting
Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies
Conditions: Neoplasms, Peritoneal Neoplasms
Last Updated: April 29, 2021
Status: Active, not recruiting
Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma
Conditions: Adenocarcinoma, Mesothelioma, Carcinoma, Ovarian Epithelial
Last Updated: April 23, 2021
Status: Active, not recruiting
Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma
Conditions: Mesothelioma, Lung Neoplasms
Last Updated: April 23, 2021
Status: Active, not recruiting
TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients
Conditions: Mesothelioma
Last Updated: April 11, 2021
Status: Active, not recruiting
Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients
Conditions: Mesothelioma
Last Updated: March 24, 2021
Status: Active, not recruiting
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
Conditions: Carcinoma, Renal Cell, Mesothelioma
Last Updated: March 19, 2021
Status: Active, not recruiting
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
Conditions: Carcinoma, Merkel Cell, Carcinoma, Lung Neoplasms, Melanoma, Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms, Mesothelioma, Squamous Cell Carcinoma of Head and Neck
Last Updated: March 16, 2021
Status: Active, not recruiting
Screening of Alberta Asbestos Exposed Workers for Lung Cancer and Mesothelioma
Conditions: Lung Neoplasms, Mesothelioma
Last Updated: March 4, 2021
Status: Active, not recruiting
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
Conditions: Carcinoma, Merkel Cell, Carcinoma, Carcinoma, Squamous Cell, Mesothelioma, Neuroendocrine Tumors, Nasopharyngeal Carcinoma, Lung Neoplasms, Carcinoma, Neuroendocrine
Last Updated: February 23, 2021
Status: Active, not recruiting
PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: February 8, 2021
Status: Active, not recruiting
A Study of LY3023414 in Participants With Advanced Cancer
Conditions: Neoplasms, Mesothelioma
Last Updated: February 3, 2021
Status: Active, not recruiting
Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin
Conditions: Neoplasms, Mesothelioma, Lung Neoplasms
Last Updated: January 20, 2021
Status: Active, not recruiting
Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma
Conditions: Vaccinia, Mesothelioma, Pleural Effusion, Malignant, Pleural Effusion
Last Updated: January 19, 2021
Status: Active, not recruiting
A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors
Conditions: Neoplasms
Last Updated: January 6, 2021
Status: Active, not recruiting
Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: January 5, 2021
Status: Active, not recruiting
A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549
Conditions: Carcinoma, Non-Small-Cell Lung, Melanoma, Triple Negative Breast Neoplasms, Mesothelioma, Neoplasms, Squamous Cell, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Adrenocortical Carcinoma
Last Updated: December 3, 2020
Status: Active, not recruiting
MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: October 19, 2020
Status: Active, not recruiting
A Randomised Phase II Open-label Study With a Phase Ib Safety lead-in Cohort of ONCOS-102, an Immune-priming GM-CSF Coding Oncolytic Adenovirus, and Pemetrexed/Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: October 6, 2020
Status: Active, not recruiting
Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma.
Conditions: Mesothelioma
Last Updated: August 18, 2020
Status: Active, not recruiting
A Double Blind, Placebo Controlled, Randomized Phase II Study Evaluating Gemcitabine With or Without Ramucirumab , for II Line Treatment MPM
Conditions: Mesothelioma
Last Updated: July 29, 2020
Status: Active, not recruiting
Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy
Conditions: Mesothelioma
Last Updated: July 22, 2020
Status: Active, not recruiting
Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma
Conditions: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Mesothelioma
Last Updated: June 30, 2020
Status: Active, not recruiting
A Study of Pembrolizumab in Combination With Cisplatin and Pemetrexed in Advanced Malignant Pleural Mesothelioma (MPM) (MK-3475-A17)
Conditions: Mesothelioma
Last Updated: June 26, 2020
Status: Active, not recruiting
Intracavitary Cisplatin-Fibrin Localized Chemotherapy After P/D or EPP for Malignant Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: May 26, 2020
Status: Active, not recruiting
Pembrolizumab in Treating Patients With Malignant Mesothelioma
Conditions: Mesothelioma, Lung Neoplasms
Last Updated: April 27, 2020
Status: Active, not recruiting
CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma
Conditions: Mesothelioma
Last Updated: April 20, 2020
Status: Active, not recruiting
